Zacks Research Upgrades Curaleaf (OTCMKTS:CURLF) to “Strong-Buy”

Curaleaf (OTCMKTS:CURLF) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Curaleaf Trading Down 1.6%

Shares of CURLF opened at $9.75 on Tuesday. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -25.00 and a beta of 1.51. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.56 and a quick ratio of 0.74. Curaleaf has a 1-year low of $2.83 and a 1-year high of $15.15. The company has a 50-day moving average of $7.56 and a 200 day moving average of $7.56.

Curaleaf (OTCMKTS:CURLF) last issued its earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.51. The business had revenue of $324.23 million for the quarter, compared to the consensus estimate of $316.62 million. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. On average, research analysts expect that Curaleaf will post -0.31 EPS for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.